Selective Alpha Adrenoblocker and the Risk of Development of Acute Urine Retention

##plugins.themes.bootstrap3.article.sidebar##

PDF (Українська)
Published: Oct 31, 2019
DOI: https://doi.org/10.30841/2307-5090.3.2019.185281
Keywords:
benign prostatic hyperplasia, acute urinary retention, postoperative urinary retention, tamsulosin,

##plugins.themes.bootstrap3.article.main##

Ю. М. Гурженко
State Institution «Institute of Urology of NAMS of Ukraine», Ukraine
В. В. Спиридоненко
Ukrainian Institute of Sexology and Andrology, Ukraine

Abstract

The article analyzes the modern scientific works on the effectiveness of conservative therapy for benign prostatic hyperplasia and acute urinary retention of various etiologies with tamsulosin. The use of tamsulosin in patients with benign prostatic hyperplasia has a positive effect on reducing the overall level of complications such as acute urinary retention. According to modern meta-analyzes on this problem, tamsulosin is one of the main drugs that are effectively used to reduce the risk of acute urinary retention in patients with benign prostatic hyperplasia and patients at risk of developing acute postoperative urinary retention.

##plugins.themes.bootstrap3.article.details##

How to Cite
Гурженко, Ю. М., & Спиридоненко, В. В. (2019). Selective Alpha Adrenoblocker and the Risk of Development of Acute Urine Retention. Health of Man, (3), 18–21. https://doi.org/10.30841/2307-5090.3.2019.185281
Issue
No. 3 (2019)
Section
Topical issues
Copyright (c) 2020 Ю. М. Гурженко, В. В. Спиридоненко

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

Authors retain the copyright and grant the journal the first publication of original scientific articles under the Creative Commons Attribution 4.0 International License, which allows others to distribute work with acknowledgment of authorship and first publication in this journal.

Author Biographies

Ю. М. Гурженко, State Institution «Institute of Urology of NAMS of Ukraine»

Yurii M. Gurzhenko,

Department of Sexopathology and Andrology

В. В. Спиридоненко, Ukrainian Institute of Sexology and Andrology

Volodymyr V. Spyrydonenko

References

Гурженко Ю.М., Спиридоненко В.В., Гайсенюк Ф.З. (2016) Профілактика ускладнень після оперативного втручання при доброякісній гіперплазії передміхурової залози // Здоровье мужчины, №2 (57), С. 133–138.

Wu Y.J., Dong Q., Liu L.R., Wei Q. (2013) A meta-analysis of efficacy and safety of the new α (1A)-adrenoceptorselective antagonist silodosin for treating lower urinary tract symptoms associated with BPH. Prostate Cancer Prostatic Dis;16:79–84.

Matsukawa Y., Takai S., Funahashi Y. et al. (2017) Effects of withdrawing a1-blocker from combination therapy with a1-blocker and 5a-reductase inhibitor in patients with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: a prospective and comparative trial using urodynamics. J Urol.;198:905–912.

Taub D.A., Wei J.T. (2006) The economics of benign prostatic hyperplasia and lower urinary tract symptoms in the United States. Curr Urol Rep.;7:272.

Fusco F., Palmieri A., Ficarra V. et al. (2016) a1-Blockers improve benign prostatic obstruction in men with lower urinary tract symptoms: a systematic review and metaanalysis of urodynamic studies. Eur Urol.;69:1091–1101.

Горпинченко И.И., Гурженко Ю.Н., Клименко П.М., Шуляк А.В., Спиридоненко В.В. (2010) Опыт использования комбинированной терапии ДГПЖ с применением препаратов Флосин МР и Простамол Уно // Новости медицины и фармации в мире, № 17 (340), С. 3–6.

Горпинченко И.И., Гурженко Ю.Н., Клименко П.М., Шуляк А.В., Спиридоненко В.В. (2012) ИсследованиеПРОСПЕКТ П (ПРОСтамол: Перспективы Комбинированной Терапии) при ДГПЖ // Здоровье мужчины, №1 (40), С. 56–62.

Горпинченко И.И., Гурженко Ю.Н, Клименко П.М., Шуляк А.В., Спиридоненко В.В. (2012) Опыт использования комбинированной терапии доброкачественной гиперплазии предстательной железы. Исследование ПРОСПЕКТ П Материалы конф. «Урология и нефрология: вчера, сегодня, завтра…», 1-2.11.2012, Харьков, С. 209–212.

Горпинченко И.И., Гурженко Ю.Н., Спиридоненко В.В. (2014) Исследование ПРОСПЕКТ 3 (Простамол Перспективы Комбинированной Терапии) доброкачественной гиперпазии предстательной железы // Здоровье мужчины, №3 (50), С. 12–18.

Matsukawa Y., Takai S., Funahashi Y. et al. (2017) Long-term efficacy of a combination therapy with an anticholinergic agent and an a1-blocker for patients with benign prostatic enlargement complaining both voiding and overactive bladder symptoms: a randomized, prospective, comparative trial using a urodynamic study. Neurourol Urodyn.; 36:748–754.

Гурженко Ю.Н., Спиридоненко В.В. (2015) Традиційні та нові аспекти в лікуванні доброякісної гіперплазії / За матеріалами 11 Південно-Європейського мітингу SEEM Європейської асоціації урологів // Здоровье мужчины, № 4 (55), С. 10–12.

Davidov MI, Lokshin KL, Gorbunova IS. (2015) Incidence of acute urinary retention in patients with prostatic adenoma and 8-year long tamsulosin therapy. Urologiia. Mar-Apr;(2):74-8, 80-81.

Gacci M, Sebastianelli A, Salvi M, Schiavina R, Brunocilla E, Novara G, De Nunzio C, Tubaro A, Oelke M, Gravas S, Carini M, Serni S. (2015) Tolterodine in the Treatment of Male LUTS. Curr Urol Rep. Sep;16(9):60.

Altarac S. (2006) Alpha-adrenergic blockers as a support in the treatment of acute urinary retention. Lijec Vjesn. Jul-Aug;128(7-8):233-237.

Lucas MG, Stephenson TP, Nargund V. (2005) Tamsulosin in the management of patients in acute urinary retention from benign prostatic hyperplasia. BJU Int. Feb;95(3):354-7.

Dunn CJ, Matheson A, Faulds DM. (2002) Tamsulosin: a review of its pharmacology and therapeutic efficacy in the management of lower urinary tract symptoms. Drugs Aging.;19(2):135-61.

Pushkar DY, Rasner PI, Aboyan IA, Asfandiyarov FR, Kotov SV, Kogan MI, Korneev IA, Medvedev VL, Neymark AI, Novikov AI, Pavlov VN, Tsukanov AY, Shabalkin SA, Shormanov IS. (2019) LUTS/BPH who treats? The results of the epidemiologic study. Urologiia. Apr;(1):5-15.

Pogula VR, Kadiyala LS, Gouru VR, Challa SR, Byram R, Bodduluri S. (2019) Tadalafil vs. tamsulosin in the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: a prospective, randomized study. Cent European J Urol.;72(1):44-50.

Kaplan SA. (2019) A Prospective Randomised Placebo-Controlled Study of the Impact of Dutasteride/Tamsulosin Combination Therapy on Sexual Function Domains in Sexually Active Men with Lower Urinary Tract Symptoms (LUTS) Secondary to Benign Prostatic Hyperplasia (BPH). J Urol. May;201(5):833-834.

Soliman MG, Abou-Ramadan AR, El-Abd AS, El-Tatawy HH, El-Abd SA, El-Sakka AA. (2019) Outcome of Modification of Dose and Time of Administration of Tamsulosin in Men with Abnormal Ejaculation. Urol Int.;102(4):482-486.

Yu Q, Gratzke C, Wang Y, Wang X, Li B, Strittmatter F, Herlemann A, Wang R, Tamalunas A, Waidelich R, Stief CG, Hennenberg M. (2019) New strategies for inhibition of non adrenergic prostate smooth muscle contraction by pharmacologic intervention. Prostate. May;79(7):746-756.

Karavitakis M, Kyriazis I, Omar MI, Gravas S, Cornu JN, Drake MJ, Gacci M, Gratzke C, Herrmann TRW, Madersbacher S, Rieken M, Speakman MJ, Tikkinen KAO, Yuan Y, Mamoulakis C. (2019) Management of Urinary